- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01740375
Role of Esophagectomy in Complete Responders to CCRT (ESOPRESSO)
26 augusti 2017 uppdaterad av: Sung-Bae Kim, Asan Medical Center
A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus
To investigate the role of esophagectomy in complete responders to preoperative chemoradiotherapy for squamous cell carcinoma of esophagus, patients will be randomized to either observation or esophagectomy after concurrent chemoradiotherapy.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
After completion of concurrent chemoradiotherapy, patients will be reassed and visited to multidisciplinary clinic, then, randomized to either observation or esophagectomy.
Studietyp
Interventionell
Inskrivning (Förväntat)
486
Fas
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Seoul, Korea, Republiken av, 05505
- Asan Medical Center
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
20 år till 70 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Histologically proven squamous cell carcinoma of the intrathoracic esophagus
- Surgically resectable (cT3, cT4a and/or disease with lymph node metastasis by AJCC 7th ed) esophageal cancer, as determined by Endoscopic Ultra Sound (EUS), chest CT and PET-CT
- No prior treatment for the esophageal cancer
- Age: 20-70 years
- ECOG performance status 0, 1 or 2
- Adequate hematological, renal, hepatic, pulmonary and cardiac functions defined as 6.1 Granulocytes > 1,500/microliter, Platelets > 75,000/microliter 6.2 Creatinine < 1.5 mg/dL (or CCr> 50 mg/mL), 6.3 Total bilirubin < 1.5 mg/dL 6.4 ALT and AST < 2.5 × upper normal limit 6.5 FEV1 >=1.5 L/min 6.6 Ejection fraction >= 45%
- Non-pregnant, non-lactating female patients. Sexually active patients of childbearing potential must implement effective contraceptive practices during the study when treated with chemotherapy
- Written, voluntary informed consent
Exclusion Criteria:
- Subtypes other than squamous cell carcinoma
- cT1N0M0, cT2N0M0 esophageal cancer or in situ carcinoma
- Invasion of recurrent laryngeal, phrenic or sympathetic nerve
- Invasion of the tracheobronchial tree or presence of tracheoesophageal fistula
- Invasion of major vessels (vena cava, azygos vein and aorta) by the tumor
- Malignant pleural effusion (documented by cytospin or cytology)
- Cervical esophageal cancer
- Para-aortic lymph node metastasis
- Past or current history of malignancy other than entry diagnosis except for non-melanomatous skin cancer, curatively treated carcinoma in situ of the cervix, curatively treated early gastric cancer with endoscopic mucosal resection or a cured malignancy more than 5 years prior to enrollment
- Previous chemotherapy or prior history of radiotherapy interfering with the planned radiotherapy as per protocol
- Patients with a known history of HIV seropositivity or HCV (+). Patients with HBV (+) are eligible. However, primary prophylaxis using antiviral agents (i.e. lamivudine, etc) is recommended for HBV carrier to prevent HBV reactivation during whole treatment period.
- Other serious illness or medical conditions A. Unstable cardiac disease (i.e. congestive heart failure, arrhythmia, symptomatic coronary artery disease) despite treatment, myocardial infarction within 6 months prior to study entry B. History of significant neurologic or psychiatric disorders including dementia or seizures C. Active uncontrolled infection (viral, bacterial or fungal infection) D. Other serious medical illnesses
- New York heart Association Class III/IV and history of active angina. Documented myocardial infarction within the 6 months preceding registration. Patients with a history of significant ventricular arrhythmia requiring medication or congestive heart failure. History of 2nd or 3rd degree heart blocks.
- Active infection or other serious underlying medical condition which would impair the ability of the patient to receive the planned treatment
- Dementia or altered mental status that would prohibit the understanding and giving of informed consent
- Uncontrolled diabetes mellitus: fasting glucose >150 mg/dL or patients requiring insulin therapy for glycemic control; fasting glucose >150 mg/dL or patients requiring insulin therapy for glycemic control;
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Inget ingripande: Arm B: observation:
No additional treatment after concurrent chemoradiotherapy.
However, esophagectomy will be considered as a salvage treatment for local recurrence during observation.
|
|
Experimentell: Arm A: esophagectomy
Esophagectomy will be performed preferentially within 8 weeks (maximum 12 weeks) after completion of concurrent chemoradiotherapy
|
esofagektomi
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
2-year disease-free survival (DFS) rate
Tidsram: 2 years from the enrollment of last patient
|
2 years from the enrollment of last patient
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Overall survival (OS)
Tidsram: 5 years from the enrollment of last patient
|
5 years from the enrollment of last patient
|
progression-free survival
Tidsram: 5 years from the enrollment of last patient
|
5 years from the enrollment of last patient
|
failure pattern
Tidsram: 5 years from the enrollment of last patient
|
5 years from the enrollment of last patient
|
Number of Participants with Adverse Events
Tidsram: up to 60 days after treatment
|
up to 60 days after treatment
|
Comparison of clinical complete response (cCR) vs. pathologic complete response rate (pCR) in patients who underwent esophagectomy
Tidsram: 5 years
|
5 years
|
Comparison of OS according to clinical response (CR vs PR vs SD/PD) after preoperative chemoradiotherapy among those who underwent preplanned esophagectomy;
Tidsram: 5 years from the enrollment of the last patient
|
5 years from the enrollment of the last patient
|
Comparison of OS according to metabolic response after induction chemotherapy
Tidsram: 5 years from the enrollment of the last patient
|
5 years from the enrollment of the last patient
|
Quality of life
Tidsram: 5 years from the enrollment of the last patient
|
5 years from the enrollment of the last patient
|
Comparison of PFS according to clinical response (CR vs PR vs SD/PD) after preoperative chemoradiotherapy among those who underwent preplanned esophagectomy;
Tidsram: 5 years from the enrollment of the last patient
|
5 years from the enrollment of the last patient
|
Comparison of TTF according to clinical response (CR vs PR vs SD/PD) after preoperative chemoradiotherapy among those who underwent preplanned esophagectomy;
Tidsram: 5 years from the enrollment of the last patient
|
5 years from the enrollment of the last patient
|
Comparison of PFS according to metabolic response after induction chemotherapy
Tidsram: 5 years from the enrollment of the last patient
|
5 years from the enrollment of the last patient
|
Comparison of TTF according to metabolic response after induction chemotherapy
Tidsram: 5 years from the enrollment of the last patient
|
5 years from the enrollment of the last patient
|
treatment-related mortality
Tidsram: up to 60 days after completion of treatment
|
up to 60 days after completion of treatment
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 november 2012
Primärt slutförande (Faktisk)
1 januari 2017
Avslutad studie (Faktisk)
1 januari 2017
Studieregistreringsdatum
Först inskickad
27 november 2012
Först inskickad som uppfyllde QC-kriterierna
30 november 2012
Första postat (Uppskatta)
4 december 2012
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
29 augusti 2017
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
26 augusti 2017
Senast verifierad
1 augusti 2017
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neoplasmer efter plats
- Neoplasmer, körtel och epitel
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Gastrointestinala sjukdomar
- Neoplasmer i huvud och hals
- Esofagussjukdomar
- Neoplasmer, skivepitelceller
- Esofagusneoplasmer
- Carcinom
- Karcinom, skivepitel
- Esofagus skivepitelcancer
Andra studie-ID-nummer
- Esophageal cancer AMC02
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Esofagus skivepitelcancer
-
Medtronic - MITGAvslutadEsophageal Squamous Cell Neoplasia (ESCN)Kina
-
Shandong UniversityOkändTidig Esophageal Squamous NeoplasiaKina
-
Fudan UniversityAktiv, inte rekryterandeOligorecurrent och Oligometastatic Esophageal Squamous Cell CarcinomaKina
-
Newish Technology (Beijing) Co., Ltd.RekryteringHöggradig squamous intraepitelial lesion (HSIL)Kina
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)AvslutadSteg IIIA Esophageal Adenocarcinom | Steg IIIB Esophageal Adenocarcinom | Steg IIIC Esophageal Adenocarcinom | Steg IIB Esophageal Adenocarcinom | Steg IB Esophageal Adenocarcinom | Steg IIA Esophageal AdenocarcinomFörenta staterna
-
Fundació Institut de Recerca de l'Hospital de la...RekryteringCervikal intraepitelial neoplasi | Livmoderhalsdysplasi | Squamous intraepitelial lesioner i livmoderhalsenSpanien
-
Hoffmann-La RocheAvslutadIcke-Squamous icke-småcellig lungcancerTyskland
-
Mabwell (Shanghai) Bioscience Co., Ltd.Har inte rekryterat ännuAvancerat clear cell renal cell carcinom
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)AvslutadAdenocarcinom i Gastro-oesofageal Junction | Steg IIIA Esophageal Adenocarcinom | Steg IIIB Esophageal Adenocarcinom | Steg IIIC Esophageal Adenocarcinom | Steg IIB Esophageal AdenocarcinomFörenta staterna
-
Memorial Sloan Kettering Cancer CenterIntegra LifeSciences CorporationAvslutadEsophageal AdenocarcinomFörenta staterna
Kliniska prövningar på esofagektomi
-
Shanghai Zhongshan HospitalZhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... och andra samarbetspartnersRekryteringEsofagus skivepitelcancer Steg II | Esofagus skivepitelcancer Steg IIIKina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RekryteringEsophagogastric Junction CarcinomaKina